Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.
Research in 2011 regarding β-cell destruction, early immunointervention trials and development of late complications in type 1 diabetes mellitus have highlighted the heterogeneity of this disease. Patient phenotyping should be performed for the implementation of tailored therapies, especially taking into account the age at which the disease is diagnosed.